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Abstract
Vulvovaginal atrophy (VVA) is a chronic disorder that commonly occurs in postmenopausal
women, whose symptoms are recognized among the most frequent and bothersome
symptoms associated with menopause. The principal therapeutic goal in managing VVA is to
relieve symptoms as well as to restore the vaginal environment to a healthy state. However,
despite its high prevalence and negative impact on quality of life, VVA is underreported by
women, underrecognized by gynecologists, and therefore, undertreated. In the light of the new
development of treatment options for VVA, we here provide an updated expert opinion on the
management of VVA. In particular, we strongly recommend that HCPs proactively start an open
discussion with their postmenopausal patients about urogenital symptoms. Treatment should
be started as early as the first symptoms of VVA occur and should be maintained over time, due
to the chronicity of the conditions. Many treatment options are now available and therapy
should be individualized, taking the woman’s preference in consideration.
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Introduction
Vulvovaginal atrophy (VVA) is a chronic disorder that commonly
occurs in postmenopausal women. The symptoms are usually
progressive in nature and deteriorate with time from the
menopausal transition. The most prevalent symptoms are vaginal
dryness, vaginal irritation, itching and soreness, dyspareunia,
vaginal bleeding associated with intercourse, and atypical
discharge [1–4]. VVA is due to loss of estrogen production in
postmenopausal women [5]. The term genitourinary syndrome of
menopause (GSM) has been proposed following a consensus
conference held in May 2013 [6]. GSM includes not only VVA
but also signs and symptoms involving urinary organs and the
pelvic floor. We here focus on VVA symptoms that, together with
vasomotor symptoms, are recognized as the most frequent and
bothersome symptoms associated with menopause and can have a
large impact on the quality of life (QoL) of the menopausal
woman. The principal therapeutic goal in managing VVA is to
relieve symptoms as well as to restore the vaginal environment to
a healthy state [2].
In recent large cohort surveys in Western populations, 45–63%
of postmenopausal women reported that they had experienced
vulvovaginal symptoms [7], most commonly vaginal dryness;
other commonly reported symptoms include dyspareunia, vaginal
irritation, itching sensation, vaginal tenderness, and vaginal
bleeding or spotting during intercourse [7–9]. The VIVA
(Vaginal Health: Insights, Views & Attitudes) international
survey obtained information from 3520 postmenopausal women
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aged 55–65 years living in Europe and the US, reporting 45% of
women experiencing vaginal symptoms [8]. A very recent
analysis of the data from the International Women’s Health
(IWH) Study, about postmenopausal women aged 40–75 years in
the US and major European countries, showed that the prevalence
of VVA symptoms varied between 40% [Germany] and 54%
[Spain], with half of women reporting their symptoms as either
moderate or severe [10]. Moreover, VVA symptoms were
associated with clinically meaningful decrements in QoL, com-
parable to serious conditions such as arthritis, chronic obstructive
pulmonary disease, asthma, and irritable bowel syndrome. In
Italy, a multicenter observational study, the AGATA study,
recruited 913 females, aged 59.3 ± 7.4 years, asking for a routine
gynecological examination. Based on patient’s sensation of
vaginal dryness, any objective sign of VVA and a vaginal
pH45, VVA was diagnosed with a prevalence ranging from
64.7% to 84.2%, starting from 1 to 6 years after menopause.
Symptoms reported by women with VVA were vaginal dryness
(100%), followed by dyspareunia, burning, itching, and dysuria.
Only 30% of women had had a previous diagnosis of VVA/GSM.
The CLOSER (The CLarifying Vaginal Atrophy’s Impact On
SEx and Relationships) survey evaluated the impact of VVA on
the physical and emotional aspects of sexual relationships
between 4100 postmenopausal women and their male partners
across Europe, Canada, and the US [11]. Having sex less often
and less satisfying, and putting off having sex (women: 35%, men:
14%) were the main effects of VVA. The European REVIVE
Study [12], on a surveyed sample of 3768 postmenopausal women
aged 45–75 years, found that the most common VVA symptom
was vaginal dryness (70%), and that VVA had a significant impact
on the ability to be intimate, to enjoy sexual intercourse, and to
feel sexual spontaneity, with an overall reduction of sexual drive.
Despite its high prevalence and negative impact on QoL, VVA
is underreported by women, underrecognized by gynecologists,
and therefore, undertreated [13,14]. There are multiple reasons for
this [14,15]. Women feel embarrassed to complain about this
problem, health-care professionals (HCPs) also feel uncomfort-
able discussing sexual issues and have limited time to face such a
discussion; moreover, they often are not fully aware of the
available treatment options that may be both hormonal and
nonhormonal. Improved management of VVA symptoms is
required to alleviate the impact of VVA on the QoL of affected
women. The North American Menopause Society (NAMS) in
2013 and the European Menopause Andropause Society (EMAS)
in 2015 focused on VVA and its treatment, underlining that
clinicians can improve the sexual health and QoL of postmeno-
pausal women by educating women about, diagnosing, and
appropriately managing symptomatic VVA [16–18]. Palacios and
Mejias [19] recently reviewed the drugs for the treatment of
menopausal symptoms, showing that there are increasing numbers
of available therapies, including hormonal and nonhormonal
treatments, and other are still under study. This rich scenario
opens up new options that may increase the number of women for
whom a suitable treatment may be available.
In the light of the new development of treatment options for
VVA, we thought that it was timely to provide an updated expert
opinion on the management of VVA.
Methods
The activity comprised different steps. A panel of experts (the
authors), composed by six gynecologists identified on the basis of
their expertise in treating menopause-associated disorders, par-
ticipation in clinical trials, and regional distribution across Italy,
was assembled and held a first meeting in July 2015. First, the
Expert Panel decided to perform a comprehensive literature
review as a basis to produce the expert statements. In a subsequent
meeting, the Expert Panel formulated a provisional set of
statements. In October 2015, these statements were presented
for discussion, amendment, and voting to a wider panel of 23
gynecologists with specific expertise in menopause health,
selected from throughout Italy. First, the whole group voted on
the level of agreement with each provisional statement using a 9-
point numerical rating scale (1¼ do not agree at all, 9¼ agree
completely). Statements reaching the average score of at least 8
were accepted straightforward, while those obtaining a mean
score58 were subjected to further discussion, amended conse-
quently, voted again, and eventually accepted if obtaining a mean
score 8.
Results and discussion
Most statements obtained a high level of agreement (8) from the
first vote. Minor changes, in terms of rewording, better specifi-
cations, and clarifications, were introduced to the few statements
that did not reach immediate consensus, and at the second vote all
statements reached an agreement score8. The approved final
statements are presented and discussed hereafter.
1. VVA, currently framed within the GSM, includes genital and
sexual symptoms involving vulva and vagina with anatomical-
functional changes related to age and lack of estrogens.
Portman et al. [6] first defined GSM as a collection of
symptoms and signs associated with a decrease in estrogen and
other sex steroids involving changes to external genitals, urethra,
and bladder. The syndrome may include but is not limited to
genital symptoms of dryness, burning, and irritation; sexual
symptoms of lack of lubrication, discomfort or pain, and impaired
function; and urinary symptoms of urgency, dysuria, and recurrent
urinary tract infections [17]. The panel of experts thinks that the
term VVA is comprised within the GSM but more specifically
applies to those of the above-cited signs and symptoms that
strictly involve genital organs and genito-sexual symptoms,
excluding urinary organs and symptoms. From an anatomical
point of view, the term VVA refers specifically to changes in the
vulvovaginal surface, that on examination is thin, pale, and dry,
narrowing of the vagina, especially in the absence of sexual
activity, thinning of the vaginal lining that becomes less elastic
and progressively smoother as rugal folds decrease [14,20].
2. VVA prevalence varies, according to different epidemio-
logical studies, to the parameters considered for diagnosis, and to
the age of the patients, but involves on average more than 50% of
postmenopausal women. VVA usually starts soon after menopause
(but sometimes even before) and its prevalence progressively
increases with the number of years following menopause.
The prevalence of sexual symptoms at the menopause differs
across studies; however, most of authors have been agreeing since
two decades that VVA affects more than 50% of postmenopausal
women [3,7,8,21,12]. VVA starts at the menopausal transition,
has a chronic progressive nature throughout the menopausal
status, and is not likely to resolve without intervention [21,14].
Severe VVA can result in a vaginal surface that is progressively
friable, with petechiae and ulcerations. Vulvovaginal anatomical
changes occur gradually but become more severe and distressing
with time and can make sexual intercourses very uncomfortable or
eventually impossible [16,20].
3. VVA diagnosis is based on anamnesis and clinical
examination; however, it may be useful to integrate them with
objective measures obtained through validated tools, such as the
Vaginal Health Index (VHI), which includes vaginal pH measure.
As stated above, symptoms and signs of VVA may allow
diagnosis [17,20]; however, some validated tools have been
developed that may be helpful by adding some objective measures
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to the clinical examination. Bachmann et al. [22] developed
the VHI in order to objectively assess female urogenital health
(Table 1), to follow it on a longitudinal basis, and to share the
findings with patients by decision-making about pharmacological
therapy. VHI may allow an objective and accurate assessment of
aging changes occurring in a patient’s urogenital tissue. Other
tools have been developed more recently. For instance, the Day-
to-Day Impact of Vaginal Aging (DIVA) questionnaire is a new
multidimensional structured, self-administered measure designed
to facilitate the evaluation of the impact of vaginal symptoms on
women’s activities of daily living, emotional well-being, sexual
functioning, and self-concept and body image [23].
4. In order to diagnose VVA, gynecologists should be proactive
in investigating the presence of VVA, stimulating with specific
questions, and showing availability to an open interview with the
patient on her genitourinary health and the impact of VVA on her
health and QoL.
Very recent surveys [7–9,11,24] suggest the need of HCPs
being proactive in order to help their patients to disclose the
symptoms related to VVA. During gynecological consultation,
postmenopausal women are often uncomfortable to report intim-
ate symptoms spontaneously. Furthermore, VVA is not recog-
nized as a medical condition, and data from qualitative research
have reported that women have often felt their concerns were
dismissed by HCPs as a normal part of aging, without receiving
any counseling about treatment options [25]. Another factor is the
poor awareness by women that effective and safe treatments may
be available. Also the International Vagina Dialogue Survey [26]
confirmed that there is a strong need to overcome misconceptions
and get reliable information on vaginal and sexual health. When
postmenopausal women are seen in the clinic, it is recommended
to include a gynecological pelvic examination, if suggested by
symptoms and circumstances, and to stimulate an open and
sensible conversation on the topic of intimacy [14,15], as also
indicated by recent clinical practice guidelines [16].
It has been previously reported that HCPs tend not to take a
proactive approach to sexual health management in the middle and
later life age groups, mainly because of inadequate training,
constraints of time, personal attitudes, and beliefs that sex is not a
priority for older women [27,28]. The expert panel strongly
recommends HCPs to proactively raise the subject of VVA in
their medical practice in order to encourage postmenopausal
women to overcome their ‘‘taboos’’ and openly discuss urogenital
symptoms. In the end, it is up to physicians to raise the topic of
vaginal health; they will appreciate that most women will express
relief and respond positively. It is appropriate to include questions
about vaginal symptoms, vaginal infections, recurrent urinary tract
infections, dyspareunia, and previous attempts to relieve symptoms.
Of course, one should be sensitive to the presence or absence of an
able sexual partner and whether the patient is really distressed by her
discomfort. Depending upon the specific patient, the HCP should be
able to modify his/her approach to reflect the woman’s personality
and culture [26,29].
5. Treatment of VVA should preferably begin at the onset of the
first symptoms and signs of atrophic changes of the vagina, which
may be quite early.
Since VVA is a chronic, age-dependent condition that may
worsen without appropriate treatment, early recognition and
prompt effective treatment of VVA may enhance sexual health
and the QoL of women and their partners. Treatment should be
started early [2], commencing therapy at the first symptoms of
urogenital atrophy, since this may prevent the development of the
vicious circle of worsening sexual dysfunction and urogynecolo-
gical consequences [13,22].
6. In choosing therapy, the woman’s preference should be
taken into consideration.
It must be remembered that women have individual needs, and
therefore the therapeutic approach needs to be personalized.
Women’s preference about treatment must be recorded and should
be a major criterion in the choice of therapy [2,13,16,17]. In spite
of available reassurances to the contrary, many women still fear
estrogen therapy [9,11,12]. Some patients may be uncomfortable
with vaginal estrogens. There are now several treatment options
available, that should be fully presented and explained to the
patients in order to meet their individual preferences.
7. The use of vaginal moisturizers and lubricants and the
maintenance of sexual activity may be helpful in improving
vaginal dryness-related symptoms. However, a few clinical trials
have been performed to assess the efficacy of such products.
Therapies to alleviate symptoms of VVA include nonhormonal
vaginal lubricants and moisturizers, as well as regular sexual
activity. Regular use of nonhormonal vaginal lubricants and
moisturizers may reduce friction-related irritation of atrophic
tissue during vaginal intercourse, at least in breast cancer
survivors with severe VVA, but they may provide only transient
benefit [30]. However, women with a sexual partner should be
informed that regular sexual activity/intercourse or other vaginal
stimulation helps to increase the likelihood that sexual activity
will remain comfortable in the future. A number of over-the-
counter (OTC) vaginal lubricants and moisturizers are available.
However, few clinical studies have been conducted to demonstrate
their efficacy. One randomized, controlled, but short-term study
demonstrated effectiveness of a pH-balanced gel compared with
placebo in women treated for breast cancer. Mild irritation
following administration was reported [31]. Other two studies
have shown that, although vaginal moisturizers are not as
effective in resolving vaginal dryness as hormonal treatments,
they can significantly decrease symptoms for many women
[32,33]. Another study that examined the safety of personal
moisturizers and lubricants found that a number of water-based
gels are hyperosmolar, inducing epithelial cellular toxicity [34].
There are very few data on the effects of lubricants that contain
flavors (sugar), warming properties, or solvents and preservatives
such as propylene glycol and parabens [35]. Further controlled
clinical trials are required to provide adequate evidence of
efficacy and safety of such products [36].
Table 1. Vaginal health index (Bachmann et al. [22]).
Score Overall elasticity* Fluid secretion type and consistency pH Epithelial mucosa Moisture
1 None None 6.1 Petechiae noted before contact None, mucosa inflamed
2 Poor Scant, thin yellow 5.6–6.0 Bleeds with light contact None, mucosa not inflamed
3 Fair Superficial, thin white 5.1–5.5 Bleeds with scraping Minimal
4 Good Moderate, thin white 4.7–5.0 Not friable, thin mucosa Moderate
5 Excellent Normal (white flocculent) 4.6 Not friable, normal mucosa Normal
*Lower score corresponds to greater urogenital atrophy.
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8. Treatments with vaginal estrogens proved to be efficacious,
but are associated with poor compliance (inconvenience, vaginal
discharge, difficult application, smell, and loss of spontaneity
during intercourse).
For decades, vaginal estrogens have been the gold standard for
treatment of symptomatic VVA. Estrogens delivered locally have
been for long time the preferred mode of delivery when vaginal
symptoms are the only complaint. Low-dose vaginal estrogen
therapy can provide sufficient estrogen to relieve symptoms with
minimal systemic absorption [16]. The results of the CLOSER
survey showed that the use of local estrogen treatment for vaginal
discomfort had a positive impact on relationships between
postmenopausal women and their partners, common benefits of
treatment including less painful and more satisfying sex for both
women and their partners [11]. However, there are women who
find it uncomfortable or do not want, due to personal or cultural
reasons, use vaginal products. In the EU REVIVE survey [12], the
most frequent disliked aspects of treatment were the route of
administration (‘‘do not like to touch body’’, ‘‘not discrete’’) or
the messiness. The fear of hormones was common in post-
menopausal women using vaginal prescription products. More
than half of participants showed a clear preference for an oral pill
instead of a vaginally administered product for the treatment of
VVA problems. Approved in both the US and Europe the orally
administered selective estrogen receptor modulator (SERM)
ospemifene is a new treatment option for women. Evidence of
efficacy of ospemifene is based on randomized controlled trials,
and long-term safety data are available. The approved indication
in Europe is for ‘‘treatment of moderate to severe symptomatic
vulvar and vaginal atrophy (VVA) in postmenopausal women who
are not candidates for local vaginal estrogen therapy’’ [17,37,38].
9. There are not enough data on the safety of topical estrogens
in patients with a history of breast cancer or of any other
estrogen-sensitive tumor. Therefore, such treatments should be
avoided or prescribed only following a deep discussion on
benefits and risks.
Data about low-dose topical estrogen therapy in women with
breast cancer are scarce, and their use is formally contraindicated
in women with (a history of) breast cancer [39]. In view of these
concerns, the EMAS 2015 guidelines recommend that nonhor-
monal lubricants and moisturizers should be considered first-line
[17]. The NAMS 2013 position paper states that for women with a
history of breast or endometrial cancer, management depends on a
woman’s preference, need, understanding of potential risks, and
consultation with her oncologist (Level of evidence C) [16]. Thus,
vaginal estrogens are controversial in women with estrogen-
dependent neoplasia, and extensive discussion with the patient on
the risk–benefit ratio as well as co-management with the woman’s
oncologist is encouraged. The new compound ospemifene does
not have this contraindication, if prescribed as directed after the
completion of the treatment plan for breast cancer. Further
investigation should be dedicated to the management of meno-
pausal disturbances in women with breast cancer.
10. The gynecologist should consider alternative therapeutic
options for all those patients who are not candidate to topical
estrogens.
There will be some women who do not wish to use estrogens,
or in whom estrogens are genuinely contraindicated. The devel-
opment of novel products, proven to be both efficacious and safe,
is therefore welcome. Palacios and Mejias [19] recently reviewed
the drugs for the treatment of menopausal symptoms, reporting
that there are increasing numbers of new therapies, but most of
them still have inconclusive results. Vaginal laser needs more
evidence regarding its efficacy and (long-term) safety. Therapies
with testosterone and dehydroepiandrosterone (DHEA) are still
under study [19]. Ospemifene represents currently an approved
oral alternative option for symptomatic VVA.
11. Since VVA is a chronic condition, therapy should be
continued over time, because signs and symptoms recur in most
cases.
There are no guidelines pertaining to the length of therapy. For
local estrogen therapy, there are no clinical trial safety data
extending beyond 12 months, but no time limits for duration of
therapy have been established. Since symptoms commonly return
when treatment is discontinued, treatment should not be time-
limited [15,18]. Appropriate monitoring should be considered.
The latest NAMS position paper recommends that if a woman is
at high risk of endometrial cancer or is using a higher dose of
vaginal estrogens, transvaginal ultrasound or intermittent proges-
togen therapy may be considered. On the other hand, there are
insufficient data to recommend routine annual endometrial
surveillance in asymptomatic women using vaginal estrogens
(Level of evidence C) [16]. The same paper states that with
appropriate clinical surveillance, vaginal estrogens or ospemifene
can be continued as long as bothersome symptoms are present
(Level C). In their very recent update on VVA management,
Palacios et al. state that in general it is probably prudent to review
women’s needs annually to assess efficacy and acceptability of
therapy, while updating on any new advice, information, or
treatment options [18].
Conclusions
VVA is a chronic, age-dependent condition occurring as a
consequence of postmenopausal estrogen deficiency, which may
worsen in the absence of appropriate treatment, leading to
progressive sexual dysfunction and potentially severe urogyneco-
logical consequences. Women are often reluctant to consult or
complain about VVA, so that, despite its high prevalence, this
condition remains poorly recognized and undertreated by HCPs.
This expert opinion has been produced with the objective of
expanding and better clarifying the current recommendations, in
order to help gynecologists in facing, recognizing, and promptly
managing VVA in their clinical practice. In particular, we strongly
recommend that HCPs proactively start an open discussion with
their postmenopausal patients about urogenital symptoms.
Treatment should be started as early as the first symptoms of
VVA occur and should be maintained over time, due to the
chronicity of the conditions. Many treatment options are now
available and therapy should be individualized, taking the
woman’s preference in consideration. We believe that gynecolo-
gists can do much to improve VVA by giving sufficient time and
attention to this condition, thereby restoring sexual health and
QoL of the many menopausal women who still suffer in silence.
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